Chemomab Therapeutics (NASDAQ:CMMB) Stock Lifted to Hold by Wall Street Zen

Wall Street Zen upgraded shares of Chemomab Therapeutics (NASDAQ:CMMB) to a hold rating in a research note released on Saturday morning,Wall Street Zen reports.

Separately, Weiss Ratings raised Chemomab Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, September 16th. One analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Chemomab Therapeutics has a consensus rating of “Reduce”.

Chemomab Therapeutics Trading Up 10.0%

CMMB opened at $1.43 on Friday. Chemomab Therapeutics has a 12 month low of $1.05 and a 12 month high of $3.58. The business’s 50-day moving average price is $2.14 and its 200-day moving average price is $1.86. The company has a market cap of $10.37 million, a P/E ratio of -0.67 and a beta of 0.74.

Chemomab Therapeutics (NASDAQ:CMMB) last issued its earnings results on Thursday, August 20th. The company reported ($0.27) earnings per share for the quarter, missing the consensus estimate of ($0.15) by ($0.12).

Institutional Trading of Chemomab Therapeutics

A hedge fund recently raised its stake in Chemomab Therapeutics stock. Kestra Private Wealth Services LLC grew its holdings in Chemomab Therapeutics Ltd. Sponsored ADR (NASDAQ:CMMB) by 19.3% in the 1st quarter, according to the company in its most recent filing with the SEC. The firm owned 61,710 shares of the company’s stock after buying an additional 10,000 shares during the quarter. Kestra Private Wealth Services LLC owned approximately 0.86% of Chemomab Therapeutics worth $97,000 at the end of the most recent quarter. Institutional investors own 46.05% of the company’s stock.

About Chemomab Therapeutics

Chemomab Therapeutics Ltd. is a clinical-stage biotechnology company focused on developing therapies for chronic inflammatory and fibrotic diseases. The company’s research is based on the role of CCL24, a chemokine believed to contribute to inflammation, tissue remodeling and fibrosis across multiple organs.

Chemomab’s lead product candidate is CM-101, an investigational monoclonal antibody designed to block CCL24 activity. The company is evaluating CM-101 in diseases including systemic sclerosis, also known as scleroderma, and primary sclerosing cholangitis, a chronic liver disease.